Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31113396 | 0.98 | CA1 (0.38) | KMT2ACA1CA2CA4ACHE | |
| SCHEMBL2044931 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL1660756 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL727453 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL1659708 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL2044674 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL2044296 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL1660610 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL2045753 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 | |
| SCHEMBL1660612 | 0.72 | KMT2A (0.34) | KMT2ACA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353141-B1 | PROCESS FOR PREPARING 3-METHYLCYCLOPENTADECANE-1,5-DIOL | BASF SE (DE) | 2019-11-06 | — | — | EP | disclosed |
| US-10196332-B2 | Process for preparing 3-methylcyclopentadecane-1,5-diol | BASF SE (DE) | 2019-02-05 | — | — | US | disclosed |
| EP-0013995-B1 | PROCESS FOR THE PREPARATION OF ACETYLENIC MACROCYCLIC KETONES | FIRMENICH SA (CH) | 1982-12-29 | — | — | EP | disclosed |
| US-4296258-A | Process for the preparation of macrocyclic ketones | FIRMENICH SA (CH) | 1981-10-20 | — | — | US | disclosed |
| EP-0013995-A1 | Process for the preparation of acetylenic macrocyclic ketones | FIRMENICH SA (CH) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196332-B2 | Process for preparing 3-methylcyclopentadecane-1,5-diol | MSMO1, OPRD1, OR51E2 | KMT2A 2223/4885CA1 1881/4885CA2 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.